The Latest in ASTCT Advocacy: January 2026
Congress Progress in FY2026 Funding Stalled
The 2026 Minibus, a bipartisan package to fund the U.S. Department of Health and Human Services (HHS) and five other federal agencies through September 30, 2026, enjoyed rare bipartisan, bicameral support until national unrest regarding the Trump administration’s immigration policies gave enough lawmakers pause. In addition to HHS funding, the 2026 Minibus funds the U.S. Department of Homeland Security (DHS), which covers FEMA, TSA and ICE operations.
Just last week, the Minibus sailed through the usually contentious House only to hit an impasse in the Senate due to concerns with recent ICE activity. On January 29, enough Republican Senators joined their Democratic colleagues in voting down the Minibus and called for the White House to negotiate on DHS reform.
While details are still emerging, it is likely that the White House will strike an agreement with concerned lawmakers to fund HHS, Defense, Labor, Education and Transportation and Housing—the other five agencies included in the Minibus—and provide short-term stopgap funding for DHS until lawmakers and the White House can come to an agreement on ICE parameters.
Congress has until January 30 to pass legislation to fund these agencies before the federal government enters a partial shutdown. The House, which does not reconvene until the first week of February, would need to approve any changes that the Senate makes to the Minibus, so a shutdown is almost inevitable at this point. After coming off of the longest government shutdown in history in November, lawmakers and the White House have no appetite for a second shutdown regarding 2026 funding.
FY2026 HHS Highlights
While lawmakers may make changes to the Minibus that affect DHS provisions, the HHS provisions will likely remain unchanged. Here’s a highlight of HHS funding for FY2026:
- Includes $116.6B in discretionary funds to HHS.
- Allocates $~49B—a $415 million increase over the 2025 levels—to NIH.
- Includes language that prevents the Trump administration from capping or restructuring funding for research overhead.
- Rejects the Trump administration’s $20B request to create a new agency called the Administration for a Health America.
- Limits, but does not prohibit, forward funding grants.
- Includes $4.6B in funding to community health centers.
- Delays cuts to disproportionate share hospitals through FY 2028.
- Includes S.932/H.R.1262, the Give Kids a Chance Act, which boosts research into pediatric uses of cancer drugs by reauthorizing and improving the Rare Pediatric Disease Priority Review Voucher Program.
- Includes S. 752/H.R. 1509, the Accelerating Kids Access to Care Act, which fast-tracks physician’s out-of-state Medicaid enrollment processes to help pediatric patients receive timely care.
- Expands most telehealth flexibilities through the end of 2027 and the hospital-at -home program through September 2030.
- Includes language that targets operational practices of pharmacy benefit managers to increase accountability and transparency and requires PBMs to pass through rebates to commercial plans to help cut drug costs.
- Provides a ~3.1 percent increase in Medicare payments to physicians participating in Advanced Alternative Payment Models.
- The proposed legislation does not include any extension to ACA premium subsidies
Next Steps
This bill in some form will eventually reach the President’s desk for signature. While the HHS funding provisions exclude many of the Executive Branch’s 2026 requests, the interest of keeping the government open may prompt the President to sign off on funding the government through September 30, 2026. Both the Legislative and Executive Branches have already begun to focus on the FY2027 budget, which needs to be signed into law by October 1, 2027. With mid-term campaign season in full force, there is even less interest in a government shutdown this fall.
ASTCT Participates in CAR T Congressional Open House
Last week, ASTCT joined other patient advocacy organizations on Capitol Hill to educate Congressional staff on the importance of increasing access to CAR T therapy. The open house brought together patients, providers and caregivers from across the country to offer a comprehensive, real-world perspective on the promise and potential of this life-saving treatment.
ASTCT wishes to thank U.S. Representatives Ami Bera (D-CA) and Mike Kelly (R-PA) and members of the House Health Care Innovation Caucus for their leadership and support to recognize, celebrate, and increase access to CAR T therapies.
“CAR T-cell therapy is a potentially curative treatment, however many eligible patients do not get the opportunity to benefit from this treatment. By educating and increasing policymakers’ awareness and understanding of CAR-T cell therapy, we can have the vital conversations required to help many more eligible patients access this treatment and achieve a cure.”
U.S. Representatives Mike Kelly (R-PA) and Ami Bera (D-CA)
Government Relations and Medicare Policy Updates at the 2026 Tandem Meetings
Join us at the 2026 Tandem Meetings on Friday, February 6, for a series of government relations and Medicare updates. These sessions will provide an overview of ASTCT's government relations strategy in 2026 and cover the latest developments in Medicare coverage and reimbursement policy related to transplantation, CAR-T, and related cellular therapies.
- February 5 | 4:05 PM MST — Meaningful Advocacy When it Matters Most
- February 6 | 8:30 AM MST — An Overview of ASTCT Government and Payer Relations in 2026
- February 6 | 9:05 AM MST — Medicare Updates: SCT, CAR-T and Other Cell and Gene Therapy Updates
- February 7 | 8:00 AM MST — From Approval to Access: Collaborating with Payers on Coverage Policy
- February 7 | 3:15 PM MST — Tele-What? Understanding Medicare’s Telemedicine and Remote Patient Monitoring Codes – and How to Bill for Them